General Information of DTT (ID: TTO7LKR)

DTT Name Tyrosine-protein kinase Mer (MERTK) DTT Info
Gene Name MERTK

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
6 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [1]
ONO-7475 DMV6GX7 Acute leukaemia 2A60 Phase 1/2 [2]
INCB81776 DMFOXGB Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
MRX-2843 DMM5N8P Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
PF-07265807 DMSMNRQ Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
RXDX-106 DM6NVTR Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Clinical Trial Drug(s)
4 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
G749 DMC7HIS Discovery agent N.A. Investigative [7]
LDC1267 DMH7R6L Discovery agent N.A. Investigative [8]
UNC2025 DMCU59W Glioblastoma of brain 2A00.00 Investigative [9]
UNC569 DMJL6ZM Acute lymphoblastic leukaemia 2A85 Investigative [10]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477.
4 The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630.
5 National Cancer Institute Drug Dictionary (drug name PF-07265807).
6 National Cancer Institute Drug Dictionary (drug name RXDX106).
7 G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood. 2014 Apr 3;123(14):2209-19.
8 The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12.
9 MerTK as a therapeutic target in glioblastoma. Neuro Oncol. 2018 Jan 10;20(1):92-102.
10 UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013 Nov;12(11):2367-77.